Immunovant reports IMVT-1402 shows 72.7% ACR20 response in rheumatoid arthritis trial

Immunovant announced positive Week 16 results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis, with response rates of 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70. The company discontinued batoclimab development to focus on IMVT-1402, which has multiple clinical programs underway with topline data expected in 2026-2027.